LUDWIG ENTERPRISES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LUDWIG ENTERPRISES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $217 | Mar 16, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.24M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($3.02M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($2.46M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($965.2K) | Apr 16, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.77M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($1.30M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.38M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $560.5K | Apr 16, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $231.6K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $165.6K | Mar 16, 2026 |
| FY2024 | Aug 31, 2024 | $100.8K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $411.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $113.2K | Apr 16, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($644.8K) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($660.3K) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($647.9K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($444.8K) | Apr 16, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $247.5K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $197.6K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $112.5K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $516.2K | Apr 16, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.64M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $2.58M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.57M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.34M | Apr 16, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.39M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($2.38M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($1.46M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($826.2K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($57.7K) | Apr 16, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.50M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($7.26M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($4.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.79M) | Apr 16, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $217 | Mar 16, 2026 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $100.0K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $1.23M | Apr 16, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 162.57M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 160.51M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 155.46M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 315.19M | Apr 16, 2024 |